Eureka AIR delivers breakthrough ideas for toughest innovation challenges, trusted by R&D personnel around the world.

BCMA (B-cell maturation antigen) chimeric antigen receptor on basis of single-domain antibodies and application of BCMA chimeric antigen receptor

A chimeric antigen receptor and carrier technology, applied in receptors/cell surface antigens/cell surface determinants, antibody medical components, antibody mimics/scaffolds, etc., can solve repeated recurrence, patient survival rate less than 20%, etc problem, to achieve the effect of strong lethality, strong lethal effect, and strong specificity

Active Publication Date: 2019-01-04
SHANGHAI SIMNOVA BIOTECHNOLOGY CO LTD
View PDF2 Cites 23 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Many patients will relapse repeatedly after suspending treatment, and the 5-year survival rate of patients after relapse is less than 20%

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • BCMA (B-cell maturation antigen) chimeric antigen receptor on basis of single-domain antibodies and application of BCMA chimeric antigen receptor
  • BCMA (B-cell maturation antigen) chimeric antigen receptor on basis of single-domain antibodies and application of BCMA chimeric antigen receptor
  • BCMA (B-cell maturation antigen) chimeric antigen receptor on basis of single-domain antibodies and application of BCMA chimeric antigen receptor

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1B

[0092] Example 1 BCMA single domain antibody VHH gene acquisition

[0093] 1) Construction of BCMA single domain antibody library

[0094] Adult healthy alpacas were immunized with multiple subcutaneous injections on the back of the neck with BCMA antigen purchased from Beijing Yiqiao Shenzhou. During immunization, add antigen and an equal volume of Freund's adjuvant, immunize in 4-6 times, follow up and observe the absorption of mass at the injection site to confirm the correct immunization. The interval between immunizations is 7-15 days. After the 4th immunization, blood is collected to determine the antigen immune titer. When the titer reaches 10,000 times or more (ELISA method), about 100ml of blood is collected, lymphocytes are separated, RNA is extracted, and reversed. It was recorded as cDNA, and the variable region fragment VHH of alpaca heavy chain antibody was amplified by two PCRs. The VHH fragment is constructed into a phage display library, and the product of t...

Embodiment 2

[0099] Example 2 Construction of Chimeric Antigen Receptor Gene Vector

[0100] Two sections of genes were synthesized by Zhongmei Taihe Company, one section of nucleotide sequence SEQ ID NO: 15 contained in BCMA sdAb I prepared in Example 1; one section is the designed 2nd generation CAR structural gene (CD8a hinge region, transmembrane domain+ 4-1BB co-stimulatory domain + CD3ζ intracellular signaling domain, the nucleotide sequence encoding the 2nd generation CAR structural gene comprising these domains is shown in SEQ ID NO: 16). After obtaining the synthetic gene, carry out molecular cloning, carry out the construction of BCMA CAR, obtain the PCR product of SEQ ID NO:15 and SEQ ID NO:16 by PCR, carry out overlapping PCR, obtain the BCMACAR gene (the nucleus of which two fragments are connected together) The nucleotide sequence is shown in SEQ ID NO: 12); the lentiviral Pre vector and the BCMA CAR gene were digested, ligated, transformed, cloned, plasmid extracted, and seq...

Embodiment 3B

[0105] Example 3 Preparation of BCMA Chimeric Antigen Receptor Lentivirus

[0106] The day before packaging the virus, trypsinize 293T cells (purchased from ATCC), 1×10 7 Cells / dish were planted in 10cm culture dish. When transfecting cells, except for the Pre-Lenti-EF1-BCMA plasmid prepared in Example 2, each plasmid needs to be co-transfected with packaging plasmids psPAX2 and pMD2.0G. Among them, 5 μg of Pre-Lenti-EF1-BCMA, 3.75 μg of psPAX2 plasmid and 1.25 μg of pMD2.0G plasmid were used. For transfection, add the mixture of the above three plasmids to 500 μl MEM medium, add 25 μl Lipofectamine (liposome) 2000 reagent to 500 μl MEM medium in another microcentrifuge tube, and then add the diluted transfection reagent one by one Add dropwise on top of the diluted plasmid, mix well, centrifuge, and stand at room temperature for 20 minutes. Finally, add the mixture of plasmid and transfection reagent into a 10cm culture dish, shake gently 10 times, mix well, and put it in t...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention relates to a chimeric antigen receptor (CAR) and application thereof. The CAR comprises BCMA (B-cell maturation antigen) binding structural domains, transmembrane structural domains, oneor a plurality of co-simulation structural domains and intracellular signal transduction structural domains. The BCMA binding structural domains comprise heavy chain complementary determining regionsHCDR 1-3, and amino acid sequences of the HCDR 1-3 are sequentially shown as SEQ ID NO:1-3.

Description

technical field [0001] The application belongs to the field of immune cell therapy, in particular, it relates to a single-domain antibody-based BCMA chimeric antigen receptor and its application. Background technique [0002] Multiple myeloma (MM) is a hematologic malignancy that occurs in the bone marrow and is characterized by the accumulation of clonal plasma cells. Treatment options focus primarily on plasma cell apoptosis and / or reduction of osteoclast activity (e.g., chemotherapy, thalidomide, lenalidomide, bisphosphonates, and / or proteasome inhibitors such as boron Tezomib or carfilzomib). Multiple myeloma is currently an incurable disease, with only about 45% of patients surviving 5 years after diagnosis. Many patients will relapse repeatedly after suspending treatment, and the 5-year survival rate of patients after relapse is less than 20%. [0003] In recent years, chimeric antigen receptor T-cell immunotherapy (CART) has become one of the most promising tumor...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): C07K19/00C12N15/62C12N5/10A61K35/17A61P35/00A61P35/02
CPCA61P35/00A61P35/02C12N5/0636C12N5/0646C07K14/7051C07K16/2878C07K2319/74C07K2319/33C07K2319/03C07K2319/00C07K2317/622C07K2317/565C12N2510/00A61K39/464417A61K39/4631A61K39/4611A61K2239/46C07K2317/569C07K2317/22C07K2317/53A61K35/17
Inventor 张继帅李胜华黄启彬苏红昌
Owner SHANGHAI SIMNOVA BIOTECHNOLOGY CO LTD
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com